Novo Nordisk’s weight-loss drug patent loss sparks a ‘gold rush’ for generic drugmakers

India's weight-loss drug market is seeing a major shift. Generic versions of Novo Nordisk's semaglutide are now available at lower prices. This is impacting Eli Lilly's drug sales. The market is expected to grow significantly. Indian drugmakers are launching these affordable alternatives rapidly. This marks a new era for obesity treatments in the country.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/cHqPBxZ
via IFTTT